Welcome to Paid Research Studies


Browse Locations ... United States» ... Iowa» ... Cedar Rapids






  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Hormone-resistant Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: exemestane;   Drug: entinostat;   Drug: goserelin acetate;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
    Interventions:   Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
    Recruiting - verified October 2014

  • Conditions:   Depressive Symptoms;   Clinical Depression
    Interventions:   Other: Road Tour;   Other: Boatload of Crosswords
    Sponsor:   University of Iowa
    Recruiting - verified October 2014

  • Condition:   Breast Cancer
    Interventions:   Other: Educational DVD 1;   Other: Educational DVD 2
    Sponsor:   Amgen
    Recruiting - verified October 2014

  • Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting - verified October 2014

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Sirukumab;   Drug: Sirukumab;   Drug: Sirukumab
    Sponsors:   Janssen Research & Development, LLC;   GlaxoSmithKline
    Recruiting - verified October 2014

  • Condition:   Chemotherapy-Induced Nausea and Vomiting
    Interventions:   Drug: Fosaprepitant dimeglumine;   Drug: Fosaprepitant Placebo;   Drug: Dexamethasone;   Drug: Ondansetron;   Drug: Dexamethasone Placebo;   Drug: Ondansetron Placebo;   Drug: Rescue Therapy
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified September 2014

  • Condition:   Colorectal Neoplasms
    Intervention:   Drug: Regorafenib (BAY73-4506)
    Sponsor:   Bayer
    Available - verified October 2014

  • Conditions:   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
    Interventions:   Biological: ofatumumab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography with radiolabeled targeting agents;   Radiation: fludeoxyglucose F 18
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
    Interventions:   Radiation: radiation therapy;   Drug: paclitaxel;   Drug: carboplatin;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Stage IV Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
    Interventions:   Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550
    Sponsor:   Pfizer
    Recruiting - verified October 2014

  • Conditions:   Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Intervention:   Genetic: cytogenetic analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified October 2014